
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4330650/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
2	Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2009, 27, 4515-4521.	1.6	341
3	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
4	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
5	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment, 2011, 128, 703-711.	2.5	223
6	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncology, 2017, 3, 1654.	7.1	208
7	Advances in Breast Cancer: Pathways to Personalized Medicine. Clinical Cancer Research, 2008, 14, 7988-7999.	7.0	165
8	Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. Journal of Clinical Oncology, 2018, 36, 2863-2871.	1.6	158
9	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapyâ€related leukemia. Cancer, 2016, 122, 304-311.	4.1	129
10	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nature Communications, 2021, 12, 4423.	12.8	111
11	Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. PLoS Genetics, 2010, 6, e1001029.	3.5	82
12	High prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in unselected Nigerian breast cancer patients. International Journal of Cancer, 2012, 131, 1114-1123.	5.1	81
13	Inherited Breast Cancer in Nigerian Women. Journal of Clinical Oncology, 2018, 36, 2820-2825.	1.6	80
14	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications, 2018, 9, 4181.	12.8	77
15	The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon. Gut, 2016, 65, 456-464.	12.1	71
16	A genome-wide association study of breast cancer in women of African ancestry. Human Genetics, 2013, 132, 39-48.	3.8	70
17	Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients. Oncotarget, 2016, 7, 55231-55248.	1.8	70
18	Hormone Replacement Therapy and Breast Cancer: Heterogeneous Risks by Race, Weight, and Breast Density, Journal of the National Cancer Institute, 2013, 105, 1365-1372.	6.3	65

#	Article	IF	CITATIONS
19	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis, 2012, 33, 835-840.	2.8	64
20	De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clinical and Experimental Metastasis, 2017, 34, 457-465.	3.3	60
21	Needle Exchange and Injection-Related Risk Behaviors in Chicago. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 108-114.	2.1	58
22	Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. Gynecologic Oncology, 2017, 146, 566-571.	1.4	58
23	Reproductive and hormone-related outcomes in women whose mothers were exposed in utero to diethylstilbestrol (DES): A report from the US National Cancer Institute DES Third Generation Study. Reproductive Toxicology, 2019, 84, 32-38.	2.9	51
24	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Human Molecular Genetics, 2016, 25, ddw305.	2.9	50
25	β-catenin regulates <i>c-Myc</i> and <i>CDKN1A</i> expression in breast cancer cells. Molecular Carcinogenesis, 2016, 55, 431-439.	2.7	48
26	Case-Control Study of Body Size and Breast Cancer Risk in Nigerian Women. American Journal of Epidemiology, 2010, 172, 682-690.	3.4	46
27	Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1–T2 and One to Three Positive Lymph Nodes. Annals of Surgical Oncology, 2015, 22, 4295-4304.	1.5	45
28	A functionally significant SNP in TP53 and breast cancer risk in African-American women. Npj Breast Cancer, 2017, 3, 5.	5.2	44
29	Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in <i>BRCA1</i> Mutation Carriers. Clinical Cancer Research, 2019, 25, 1786-1794.	7.0	44
30	Prediction of <i>BRCA</i> Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Journal of Clinical Oncology, 2009, 27, 1184-1190.	1.6	43
31	Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes and Control, 2012, 23, 565-574.	1.8	43
32	A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase. Breast Cancer Research and Treatment, 2013, 138, 633-641.	2.5	43
33	Alcohol Consumption and Breast Cancer Risk among Women in Three Sub-Saharan African Countries. PLoS ONE, 2014, 9, e106908.	2.5	43
34	A comprehensive examination of breast cancer risk loci in African American women. Human Molecular Genetics, 2014, 23, 5518-5526.	2.9	42
35	Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Research and Treatment, 2018, 168, 703-712.	2.5	42
36	Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose–response meta-analysis. European Journal of Epidemiology, 2020, 35, 567-578.	5.7	41

#	Article	IF	CITATIONS
37	Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. Journal of the National Cancer Institute, 2021, 113, 1168-1176.	6.3	41
38	Concordance in histological and biological parameters between first and second primary breast cancers. Cancer, 2011, 117, 907-915.	4.1	40
39	Discordance in Hormone Receptor Status Among Primary, Metastatic, and Second Primary Breast Cancers: Biological Difference or Misclassification?. Oncologist, 2014, 19, 592-601.	3.7	39
40	Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 359-367.	2.5	36
41	Influence of reproductive factors on hip fracture risk in Chinese women. Osteoporosis International, 2003, 14, 694-700.	3.1	35
42	Drug Use and HIV Risk Practices of Secondary and Primary Needle Exchange Users. AIDS Education and Prevention, 2005, 17, 170-184.	1.1	35
43	The Use of Needle Exchange by Young Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 67-70.	2.1	34
44	Cessation of injection drug use and change in injection frequency: the Chicago Needle Exchange Evaluation Study. Addiction, 2006, 101, 1606-1613.	3.3	32
45	Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Human Genetics, 2016, 135, 1145-1159.	3.8	32
46	Identification of novel common breast cancer risk variants at the 6q25 locusÂamong Latinas. Breast Cancer Research, 2019, 21, 3.	5.0	32
47	Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Research and Treatment, 2008, 110, 367-376.	2.5	31
48	Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Annals of Epidemiology, 2013, 23, 551-557.	1.9	31
49	The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. Journal of Biological Chemistry, 2016, 291, 12294-12309.	3.4	30
50	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>2</i> Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
51	Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncology, 2017, 3, 928.	7.1	28
52	Household biomass fuel use, asthma symptoms severity, and asthma underdiagnosis in rural schoolchildren in Nigeria: a cross-sectional observational study. BMC Pulmonary Medicine, 2017, 17, 3.	2.0	28
53	Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?. Cancer, 2019, 125, 213-222.	4.1	28
54	HIV Risk Practices Among Needle Exchange Users and Nonusers in Chicago. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1187-1196.	2.1	27

DEZHENG HUO

#	Article	IF	CITATIONS
55	Association of Colorectal Cancer and Prostate Cancer and Impact of Radiation Therapy. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1979-1985.	2.5	27
56	Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Research and Treatment, 2017, 162, 317-328.	2.5	27
57	Prenatal diethylstilbestrol exposure and cancer risk in women. Environmental and Molecular Mutagenesis, 2019, 60, 395-403.	2.2	27
58	Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Research, 2021, 23, 18.	5.0	27
59	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis, 2013, 34, 1520-1528.	2.8	26
60	A Tale of Two Cancers: Traveling to Treat Pancreatic and Thyroid Cancer. Journal of the American College of Surgeons, 2017, 225, 125-136e6.	0.5	26
61	Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Research and Treatment, 2018, 168, 207-220.	2.5	26
62	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	2.5	26
63	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointestinal Endoscopy, 2018, 87, 1304-1309.	1.0	25
64	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Research and Treatment, 2021, 185, 841-849.	2.5	25
65	Changes in the Sharing of Drug Injection Equipment among Street-Recruited Injection Drug Users in Chicago, Illinois, 1994–1996. Substance Use and Misuse, 2005, 40, 63-76.	1.4	24
66	Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1016-1026.	2.5	24
67	Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nature Communications, 2021, 12, 4198.	12.8	24
68	Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. Journal of Global Oncology, 2017, 3, 194-200.	0.5	23
69	Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer, 2020, 126, 4013-4022.	4.1	23
70	The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer, 2021, 127, 4072-4080.	4.1	23
71	Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. PLoS ONE, 2016, 11, e0165559.	2.5	23
72	Circulating Insulin-Like Growth Factor-1 and Risk of Total and 19 Site-Specific Cancers: Cohort Study Analyses from the UK Biobank. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2332-2342.	2.5	22

#	Article	IF	CITATIONS
73	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nature Communications, 2021, 12, 6946.	12.8	22
74	An Epidemiologic Investigation of Physical Activity and Breast Cancer Risk in Africa. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2748-2756.	2.5	21
75	Pilot study demonstrating potential association between breast cancer imageâ€based risk phenotypes and genomic biomarkers. Medical Physics, 2014, 41, 031917.	3.0	21
76	Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast, 2015, 24, 131-136.	2.2	21
77	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
78	Prevalence and Incidence of HIV Among Out-of-Treatment Injecting Drug Users, Chicago 1994–1996. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 443-450.	2.1	18
79	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. American Journal of Human Genetics, 2021, 108, 564-582.	6.2	18
80	Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. Blood, 2008, 112, 2809-2809.	1.4	18
81	Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. BMC Complementary Medicine and Therapies, 2020, 20, 93.	2.7	17
82	Needle Exchange and Sexual Risk Behaviors Among a Cohort of Injection Drug Users in Chicago, Illinois. Sexually Transmitted Diseases, 2009, 36, 35-40.	1.7	16
83	Biomass fuel exposure and asthma symptoms among rural school children in Nigeria. Journal of Asthma, 2017, 54, 347-356.	1.7	16
84	Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 636-643.	2.5	16
85	Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. New England Journal of Medicine, 2018, 378, 1746-1748.	27.0	16
86	Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. International Journal of Cancer, 2019, 145, 3321-3333.	5.1	16
87	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. European Journal of Epidemiology, 2019, 34, 591-600.	5.7	16
88	Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genetics, 2017, 13, e1006727.	3.5	14
89	Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Research and Treatment, 2012, 132, 341-345.	2.5	12
90	A Prospective Cohort Study of Prenatal Diethylstilbestrol Exposure and Cardiovascular Disease Risk. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 206-212.	3.6	12

#	Article	IF	CITATIONS
91	Breast cancer risk after fullâ€ŧerm pregnancies among A frican women from N igeria, C ameroon, and U ganda. Cancer, 2015, 121, 2237-2243.	4.1	11
92	Genetic anticipation in <i>BRCA1/BRCA2</i> families after controlling for ascertainment bias and cohort effect. Cancer, 2016, 122, 1913-1920.	4.1	11
93	Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. International Journal of Cancer, 2018, 142, 36-43.	5.1	11
94	Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Human Molecular Genetics, 2022, 31, 3133-3143.	2.9	11
95	Genetic Susceptibility to Type 2 Diabetes and Breast Cancer Risk in Women of European and African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 552-556.	2.5	10
96	Microsatellites in the Estrogen Receptor (ESR1, ESR2) and Androgen Receptor (AR) Genes and Breast Cancer Risk in African American and Nigerian Women. PLoS ONE, 2012, 7, e40494.	2.5	10
97	Hematologic toxicity in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Medicine, 2019, 8, 5609-5618.	2.8	10
98	The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML) Blood, 2004, 104, 264-264.	1.4	10
99	Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes. Journal of Surgical Oncology, 2015, 112, 809-814.	1.7	9
100	Germline Variation and Breast Cancer Incidence: A Gene-Based Association Study and Whole-Genome Prediction of Early-Onset Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1057-1064.	2.5	9
101	A longitudinal study of the prevalence and characteristics of breast disorders detected by clinical breast examination during pregnancy and six months postpartum in Ibadan, Southwestern Nigeria. BMC Women's Health, 2018, 18, 152.	2.0	8
102	Gender Identity and Sexual Orientation Identity in Women and Men Prenatally Exposed to Diethylstilbestrol. Archives of Sexual Behavior, 2020, 49, 447-454.	1.9	7
103	Has Hypofractionated Whole-Breast Radiation Therapy Become the Standard of Care in the United States? An Updated Report from National Cancer Database. Clinical Breast Cancer, 2022, 22, e8-e20.	2.4	7
104	Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Research and Treatment, 2022, 192, 639-648.	2.5	7
105	Association of breast cancer risk and the mTOR pathway in women of African ancestry in †The Root' Consortium. Carcinogenesis, 2017, 38, 789-796.	2.8	6
106	Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Molecular Carcinogenesis, 2018, 57, 1311-1318.	2.7	6
107	Development and external validation of a breast cancer absolute risk prediction model in Chinese population. Breast Cancer Research, 2021, 23, 62.	5.0	6
108	Prenatal Diethylstilbestrol Exposure and Cancer Risk in Males. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1826-1833.	2.5	6

#	Article	IF	CITATIONS
109	Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma Journal of Clinical Oncology, 2018, 36, 8564-8564.	1.6	6
110	A metaâ€analysis approach with filtering for identifying geneâ€level gene–environment interactions. Genetic Epidemiology, 2018, 42, 434-446.	1.3	5
111	Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 116-118.	2.5	5
112	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
113	Assessment of Breast Cancer Management in Sub-Saharan Africa. JCO Global Oncology, 2021, 7, 1593-1601.	1.8	5
114	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. International Journal of Epidemiology, 2019, 48, 1727-1730.	1.9	3
115	Hypofractionated Radiation Therapy for Breast Cancer: Financial Risk and Expenditures in the United States, 2008 to 2017. International Journal of Radiation Oncology Biology Physics, 2022, 112, 654-662.	0.8	3
116	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
117	252Development and validation of a breast cancer absolute risk prediction model in Chinese population. International Journal of Epidemiology, 2021, 50, .	1.9	2
118	Instrumental variable approach for estimating a causal hazard ratio: application to the effect of postmastectomy radiotherapy on breast cancer patients. Observational Studies, 2019, 5, 141-162.	0.6	2
119	Bayesian adjustment for the misclassification in both dependent and independent variables with application to a breast cancer study. Statistics in Medicine, 2016, 35, 4252-4263.	1.6	1
120	Pre- and post-treatment body weight and prognosis in a multiethnic cohort of breast cancer patients Journal of Clinical Oncology, 2018, 36, 1501-1501.	1.6	1
121	Abstract 2320: Evaluating a polygenic risk score for breast cancer in women of African ancestry. , 2020, , .		1
122	Abstract 4613: Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry. , 2020, , .		1
123	Associations between age of menarche and genetic variation in women of African descent: genome-wide association study and polygenic score analysis. Journal of Epidemiology and Community Health, 2021, , jech-2020-216000.	3.7	1
124	Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Research and Treatment, 2011, 127, 871-877.	2.5	0
125	Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening—Reply. JAMA Oncology, 2018, 4, 883.	7.1	0
126	Can We Leverage HIV Prevention Programs for Breast Cancer Interventions? Preliminary Findings From a Study in Nigerian Women Working in the Informal Work Sector. JCO Global Oncology, 2020, 6, 66-66.	1.8	0

#	Article	IF	CITATIONS
127	Abstract PS18-12: Comparative analysis of differential gene expression by ancestry using primary breast cancers from Nigeria and the cancer genome atlas (TCGA). , 2021, , .		0
128	Validation of the RSClin risk calculator using the National Cancer Database (NCDB) Journal of Clinical Oncology, 2021, 39, 549-549.	1.6	0
129	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation Blood, 2005, 106, 1818-1818.	1.4	0
130	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT) Blood, 2006, 108, 3675-3675.	1.4	0
131	Ancestry-based differences in hereditary cancer genetic testing Journal of Clinical Oncology, 2017, 35, e13107-e13107.	1.6	Ο
132	Association of breast cancer risk in women of African ancestry with genetic variants in the TET-related DNA demethylation pathway Journal of Clinical Oncology, 2017, 35, e13015-e13015.	1.6	0
133	Variation in screening rates in a multi-ethnic population-based study in Chicago Journal of Clinical Oncology, 2017, 35, 1509-1509.	1.6	Ο
134	Genomic profiling of residual tumor after neoadjuvant chemotherapy for breast cancer Journal of Clinical Oncology, 2019, 37, e12106-e12106.	1.6	0
135	Determining clinical relevance of genomic heterogeneity in an ethnically diverse cohort of newly diagnosed patients with breast cancer Journal of Clinical Oncology, 2019, 37, 3084-3084.	1.6	0
136	Population health impact of genome-driven oncology by race and ethnicity Journal of Clinical Oncology, 2019, 37, e18229-e18229.	1.6	0
137	Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Global Oncology, 2022, , .	1.8	0
138	Racial differences in interest and use of integrative medicine among patients with breast cancer Journal of Clinical Oncology, 2022, 40, 12101-12101.	1.6	0